Search This Blog

1 April 2008

FDA Probes Suicide Risk for Blockbuster Asthma Medication

Health regulators are probing a possible connection between Merck’s blockbuster asthma drug Singulair and suicidal behavior in adults and children.

The FDA decided to review the issue after receiving reports of mood and behavior changes, suicidal thinking and suicide in patients who took the drug. The FDA is also reviewing reports of behavioral changes related to similar drugs such as AstraZeneca’s Accolate and Critical Therapeutics’ Zyflo.

Singulair is used to treat stuffy nose, sneezing and other allergy symptoms as well as asthma. It is Merck's biggest selling product and one of the world's top selling medicines.


* Reuters March 27, 2008

No comments: